Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.

Avadel Pharmaceuticals plc

Wells Fargo analyst Benjamin Burnett maintained a Hold rating on Avadel Pharmaceuticals today and set a price target of $22.50. According to TipRan...

Avadel Pharmaceuticals (AVDL) Gets a Hold from Wells Fargo

Analysts fell to the sidelines weighing in on Avadel Pharmaceuticals (AVDL – Research Report) and Oncolytics Biotech (ONCY – Research Report) with ...

Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and Oncolytics Biotech (ONCY)

Avadel Pharmaceuticals ( ($AVDL) ) has issued an announcement. On November 18, 2025, Avadel Pharmaceuticals and Alkermes plc amended their original...

Avadel Pharmaceuticals Amends Agreement with Alkermes

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Avadel Pharmaceuticals (AVDL – Research Report) and Sarepta Thera...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AVDL	$23.03	+0.39%	2.72M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AVDL	$23.03	+0.4%	2.72M
3
4
5
6

AVDL

AVDL

Dividend Overview

Get Avadel Pharmaceuticals plc Data in Excel

Get Avadel Pharmaceuticals plc Data in Excel